News & Updates

ARANOTE: Darolutamide plus ADT delays progression in mHSPC

28 Feb 2025 by

The use of darolutamide (DARO) in addition to androgen deprivation therapy (ADT) is effective at improving radiological progression-free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) compared with placebo plus ADT, irrespective of disease volume, according to the subanalysis of the phase III ARANOTE trial.

ARANOTE: Darolutamide plus ADT delays progression in mHSPC

28 Feb 2025

Mevrometostat plus enzalutamide improves outcomes in mCRPC patients

27 Feb 2025 by

Treatment with mevrometostat (MEV), an enhancer of zeste homolog 2 inhibitor, in combination with enzalutamide (ENZ) results in better survival outcomes and response than ENZ alone among patients with metastatic castration-resistant prostate cancer (mCRPC), reports a study presented at ASCO GU 2025. The combined therapy also demonstrates a favourable safety profile.

Mevrometostat plus enzalutamide improves outcomes in mCRPC patients

27 Feb 2025

Product Highlight - Dutasteride, tamsulosin hydrochloride (Tamzor Duo)

20 Feb 2025

Capsule 500 mcg/400 mcg

Product Highlight - Dutasteride, tamsulosin hydrochloride (Tamzor Duo)

20 Feb 2025

AI-measured body composition predicts complications after RCx

16 Feb 2025

An artificial intelligence (AI)-based assessment of preoperative body composition can determine patients who might develop early complications following radical cystectomy (RCx), a study has shown.

AI-measured body composition predicts complications after RCx

16 Feb 2025

Penile control: Which device is favoured by men?

15 Feb 2025 by

Comparisons between two medical-grade penile control devices show that FirmTech performs better than Eddie by Giddy in terms of overall impression, likelihood of using the device in the future, and recommending it to a friend, reports a study. On the other hand, Eddie by Giddy works wonders at improving erectile firmness.

Penile control: Which device is favoured by men?

15 Feb 2025

Reintervention may occur in men undergoing AUS implantation

14 Feb 2025

There is a slight chance of reintervention within 2 years after the procedure among men who underwent artificial urinary sphincter (AUS) implantation for stress urinary incontinence (SUI) due to prostate cancer or benign prostatic hyperplasia (BPH) treatment, suggests a study.

Reintervention may occur in men undergoing AUS implantation

14 Feb 2025

Metallic better than polymeric stents for CUO management

30 Jan 2025 by

The use of Resonance metallic stent (MS) for chronic ureteric obstruction (CUO) leads to markedly longer indwelling time that prevents the higher unit cost of the stent when compared with the conventional polymeric stent (PS), reports a study in Singapore.

Metallic better than polymeric stents for CUO management

30 Jan 2025

Postexposure doxycycline brings down STI rates among people on PrEP

24 Jan 2025 by

Individuals already taking pre-exposure prophylaxis (PrEP) for HIV prevention saw sharp declines in chlamydia and syphilis cases, as well as a moderate reduction in urethral and rectal gonorrhoea, when they also took doxycycline after potential exposure (doxyPEP).

Postexposure doxycycline brings down STI rates among people on PrEP

24 Jan 2025

CAN score predicts length of stay, readmission in patients undergoing radical cystectomy

15 Jan 2025

In patients undergoing radical cystectomy for bladder cancer, an automated electronic health record score (the Care Assessment Need [CAN] score) can estimate the length of hospital stay (LOS), discharge to a skilled nursing facility, and readmission within 30 and 90 days after the procedure, reports a study.

CAN score predicts length of stay, readmission in patients undergoing radical cystectomy

15 Jan 2025

Resilience tied to better mental health, QoL in bladder cancer

14 Jan 2025

Baseline psychological resources (PR) are associated with improved mental health and quality-of-life (QoL) outcomes over time in patients with bladder cancer, suggest the results of a recent study.

Resilience tied to better mental health, QoL in bladder cancer

14 Jan 2025

News & Updates

Filter by Specialty:

Specialty:

ARANOTE: Darolutamide plus ADT delays progression in mHSPC

ARANOTE: Darolutamide plus ADT delays progression in mHSPC

Mevrometostat plus enzalutamide improves outcomes in mCRPC patients

Mevrometostat plus enzalutamide improves outcomes in mCRPC patients

Product Highlight - Dutasteride, tamsulosin hydrochloride (Tamzor Duo)

Product Highlight - Dutasteride, tamsulosin hydrochloride (Tamzor Duo)

AI-measured body composition predicts complications after RCx

AI-measured body composition predicts complications after RCx

Penile control: Which device is favoured by men?

Penile control: Which device is favoured by men?

Reintervention may occur in men undergoing AUS implantation

Reintervention may occur in men undergoing AUS implantation

Metallic better than polymeric stents for CUO management

Metallic better than polymeric stents for CUO management

Postexposure doxycycline brings down STI rates among people on PrEP

Postexposure doxycycline brings down STI rates among people on PrEP

CAN score predicts length of stay, readmission in patients undergoing radical cystectomy

CAN score predicts length of stay, readmission in patients undergoing radical cystectomy

Resilience tied to better mental health, QoL in bladder cancer

Resilience tied to better mental health, QoL in bladder cancer